ReviewHealth science reports2026
"Prognostic Significance of Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and Monocyte-to-Lymphocyte Ratios in Myeloid Neoplasms: A Systematic Review".
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are heterogeneous hematologic malignancies with variable outcomes. Inflammatory markers from routine blood counts, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), have emerged as potential prognostic biomarkers. This systematic review aimed to evaluate their prognostic and diagnostic significance in MDS and AML. Methods: A systematic search of PubMed, Web of Science, and Scopus was performed from inception to June 2026. Studies evaluating NLR, PLR, or MLR in MDS or AML were included. Lymphocyte-to-monocyte ratio values were converted to MLR using MLR = 1/LMR. Data were synthesized narratively due to heterogeneity. Results: Thirteen studies (2847 patients) met inclusion criteria. Elevated NLR, PLR, and MLR were consistently associated with shorter overall survival. NLR showed independent prognostic value in AML and higher-risk MDS (HR: 1.05-2.136). MLR demonstrated the most consistent prognostic association (cutoffs: 0.20-0.67). PLR showed context-dependent value (cutoffs: 22.14-213.2). Only one study assessed diagnostic performance, reporting excellent discrimination for NLR (AUC = 0.9169) and good performance for PLR (AUC = 0.8312). Conclusion: NLR, PLR, and MLR are accessible biomarkers that may complement risk stratification in MDS and AML. However, heterogeneity in cutoff values limits routine clinical use. Prospective standardized studies are needed to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.